Latest Content

Below you will find the latest content for Liminal BioSciences including press releases, financial documents, video & webinar updates. Specific therapeutic information can be accessed using the menu above.

  • Prometic shareholders approve name change to Liminal BioSciences Inc.

    Prometic shareholders approve name change to Liminal BioSciences Inc.

    Shareholders representing approximatively 87% of votes cast approved a special resolution authorizing the Company to amend its articles to change its name to Liminal BioSciences Inc.

    Read Article
  • Prometic reports first subject dosed in phase I clinical study with single ascending doses of PBI-4547

    Prometic reports first subject dosed in phase I clinical study with single ascending doses of PBI-4547

    PBI-4547 is a novel, orally active immune-metabolic agent which displays antidiabetic, antihyperlipidemic, anti-inflammatory and anti-fibrotic activity as shown in multiple animal models.

    Read Article
  • Prometic Life Sciences to present at H.C. Wainwright & Co. 21st Annual Global Investment Conference

    Prometic Life Sciences to present at H.C. Wainwright & Co. 21st Annual Global Investment Conference

    Members of the management team will provide a business overview and update at the H.C. Wainwright & Co. 21st Annual Global Investment Conference at 11:15 EDT on Tuesday, September 10, 2019 in New York

    Read Article
  • Prometic Life Sciences Announces Intention to change name to Liminal BioSciences Inc.

    Prometic Life Sciences Announces Intention to change name to Liminal BioSciences Inc.

    Prometic announced today its intention to change its name as part of a global rebrand in support of its new vision and values.

    Read Article
  • Press Releases

    Read More
  • Annual Report 2018

    Annual Report 2018

    2018 was once again a year filled with strong scientific and clinical program development achievements for Prometic.

    Read PDF
  • Quarterly Report 2018 Q3

    Quarterly Report 2018 Q3

    Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process along with Substantial reduction in R&D costs of up to $30 million.

    Read PDF
  • Quarterly Report Q2 2018

    Quarterly Report Q2 2018

    Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).

    Read PDF
  • Financial Reports

    Read Now
  • Board of Directors Charter 2019

    Board of Directors Charter 2019

    Read PDF
  • Code of Ethics and Business Conduct 2019

    Code of Ethics and Business Conduct 2019

    Read PDF
  • Position Description Lead Independent Director 2019

    Position Description Lead Independent Director 2019

    Read PDF
  • HR & Corporate Governance Committee Charter 2019

    HR & Corporate Governance Committee Charter 2019

    Read PDF
  • Liminal BioSciences Articles of Incorporation 2019

    Liminal BioSciences Articles of Incorporation 2019

    Prometic Life Sciences Inc. articles of incorporation and articles of amendments

    Read PDF
  • Corporate Governance

    Read More
  • Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency2:17

    Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency

    At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).

    Watch Video
  • LMNL Share Price

    View Now
  • Virtual Tour of Prometic Life Science's Manufacturing Process6:14

    Virtual Tour of Prometic Life Science's Manufacturing Process

    You will discover how our industry leading technology is now being used to extract and purify therapeutic proteins from human plasma to provide for the development of best in class products.

    Watch Video
  • ×

    Get the updates before everyone else.

    First Name
    Last Name
    * By completing and submitting this form, you understand and agree that use of Liminal BioSciences' web site is subject to Liminal BioSciences Privacy Policy
    !
    Thank you!
    Error - something went wrong!
  • Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment1:41

    Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment

    Prometic Life Science's senior director details the promising efficacy PBI-4050 alone or in combination with nintedanib demonstrated for treatment of IPF.

    Watch Video
  • Interested in Investment Opportunities?

    Contact Us
  • loading
    Loading More...